dimethylamylamine

Dimethylamylamine (DMAA) is a synthetic small molecule sympathomimetic amine originally developed and marketed by Eli Lilly and Company. Introduced in 1948 as an inhaled nasal decongestant under the brand name Forthane, it was voluntarily withdrawn from the pharmaceutical market in the 1980s. DMAA functions as an indirect sympathomimetic agent, primarily by increasing the availability of norepinephrine and interacting with the dopamine transporter, which leads to vasoconstriction, bronchodilation, and central nervous system stimulation. In the mid-2000s, it re-emerged as a common ingredient in dietary supplements marketed for weight loss, bodybuilding, and ADHD. However, its use has been linked to significant cardiovascular risks, including hypertension, myocardial infarction, and stroke, leading to regulatory bans by the FDA, the World Anti-Doping Agency (WADA), and various international health authorities.

Brand names

ForthaneGeranamine

Other names

1,3-dimethylamylamine1,3-DMAADMAAmethylhexanamine2-amino-4-methylhexane1,3-dimethylpentylamine